BMS, IMS, EMAS, RCOG and AMS joint statement on menopausal hormone therapy and breast cancer risk in response to EMA Pharmacovigilance Risk Assessment Committee recommendations in May 2020

  1. Hamoda, H.
  2. Davis, S.R.
  3. Cano, A.
  4. Morris, E.
  5. Davison, S.
  6. Panay, N.
  7. Lumsden, M.A.
  8. Hillard, T.
  9. Simoncini, T.
Aldizkaria:
Post Reproductive Health

ISSN: 2053-3705,  2053-3691

Argitalpen urtea: 2021

Alea: 27

Zenbakia: 1

Orrialdeak: 49-55

Mota: Gutuna

DOI: 10.1177/2053369120983154 GOOGLE SCHOLAR lock_openSarbide irekia editor

Garapen Iraunkorreko Helburuak

Datuen iturria: Scopus